×
HF is a severe clinical and public
health
problem that is characterized
by an increasing prevalence and
economic cost.
HF is a severe clinical and public health problem that is characterized by an increasing prevalence and economic cost. On a global level, the prevalence of HF reaches more than 23 million people. Analysis of NT-proBNP levels are used e.g., for exclusion of HF, risk stratification, and as a prognostic marker of HF.
Our studies have revealed that the majority
of antibodies specific to the central part of the NT-proBNP molecule scarcely
detect the antigen in human blood samples, which is due to glycosylation of the
central part of endogenous NT-proBNP. Glycosylation changes the epitope
availability for antibody recognition, subsequently decreasing reliable quantitation
of NT-proBNP with such antibodies in commercial assays.
For the development of NT-proBNP assays we offer variety of monoclonal antibodies, and recombinant non-glycosylated NT-proBNP antigen that can be used as a standard or calibrator in NT-proBNP assays. In addition, we offer NT-proBNP depleted EDTA plasma as a matrix for NT-proBNP assay development.
BNP is a peptide hormone with natriuretic, vasodilatory and renin inhibitory properties. The gene encoding for BNP is activated in cardiomyocytes in response to myocardial stretch due to pressure or volume overload.
Similar to NT-proBNP, BNP is associated with chronic heart disease, hypertension and diabetes, and its elevation is among the known risk factors and the prevalence of heart failure (HF) and is associated with significant morbidity and mortality.
BNP is an unstable molecule, and it contains several protease cleavage sites. Especially the N-terminus is highly susceptible to degradation. However, the ring structure of BNP molecule is relatively stable. BNP is secreted into the bloodstream and circulate in human blood, where it is efficiently cleared from the circulation as its half-life is approximately 20 minutes.
For the development of NT-proBNP assays we offer variety of monoclonal antibodies, and recombinant non-glycosylated NT-proBNP antigen thatt can be used as a standard or cabilator in NT-proBNP assys. In addition, we offer NT-proBNP depleted EDTA plasma as a matrix for NT-proBNP assay development.
Learn more:
Cat# 4BNP2, 4BNP2cc: BNP human, antibody
Cat# 4BFab5, 4BFab5cc: Immune complex
(24C5-BNP/proBNP), antibody
Cat# 4NT1, 4NT1cc: NT-proBNP human antibody
Copyright © Hytest Ltd.